Shift from a Contract Services Business Model to a Drug Discovery and Intellectual Property Licensing Business Model

The company plans to shift from a business centered on contract services to a pharmaceutical development support model focused on intellectual property licensing and in-house drug discovery. It will build a portfolio of drug discovery results and pursue commercialization by obtaining preclinical proof of concept, among other means.